Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.98)
# 2,891
Out of 5,169 analysts
106
Total ratings
28.32%
Success rate
-2.9%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Maintains: Buy | $12 → $11 | $7.53 | +46.08% | 5 | Mar 17, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $4.75 | +510.53% | 3 | Mar 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $10.66 | +97.00% | 4 | Mar 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $5.48 | +82.48% | 5 | Mar 2, 2026 | |
| MNKD MannKind | Maintains: Buy | $11 → $8 | $2.51 | +218.73% | 9 | Feb 27, 2026 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $4.29 | +203.03% | 5 | Feb 11, 2026 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $0.97 | +827.84% | 3 | Feb 10, 2026 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $20 | $12.79 | +56.37% | 3 | Feb 10, 2026 | |
| CRMD CorMedix | Maintains: Buy | $18 → $13 | $6.39 | +103.60% | 5 | Jan 23, 2026 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $6 | $0.81 | +637.10% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $46 → $60 | $36.19 | +65.79% | 8 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $1.13 | +873.45% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $10.97 | +264.63% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.71 | +369.21% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $22.44 | +167.44% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.11 | +279.15% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.24 | +709.72% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $74.96 | +61.42% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.71 | +68.15% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $6.95 | +87.05% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.06 | +195.57% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.85 | +145.61% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.34 | +178.52% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.02 | +392.61% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.75 | +11,328.57% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.04 | +99.00% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $7.76 | +5,767.18% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $18.70 | +215.51% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $179.31 | +0.39% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.29 | +9,506.99% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.42 | +16.70% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $0.85 | +2,587,827.79% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $8.85 | +464.97% | 1 | Jul 12, 2018 |
Eupraxia Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $7.53
Upside: +46.08%
Sagimet Biosciences
Mar 11, 2026
Reiterates: Buy
Price Target: $29
Current: $4.75
Upside: +510.53%
Trevi Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $21
Current: $10.66
Upside: +97.00%
Xeris Biopharma Holdings
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $5.48
Upside: +82.48%
MannKind
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $2.51
Upside: +218.73%
PolyPid
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.29
Upside: +203.03%
Cardiol Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $0.97
Upside: +827.84%
Enanta Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $12.79
Upside: +56.37%
CorMedix
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $6.39
Upside: +103.60%
Heron Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $0.81
Upside: +637.10%
Jan 9, 2026
Reiterates: Buy
Price Target: $46 → $60
Current: $36.19
Upside: +65.79%
Jan 9, 2026
Reiterates: Buy
Price Target: $11
Current: $1.13
Upside: +873.45%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $10.97
Upside: +264.63%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.71
Upside: +369.21%
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $22.44
Upside: +167.44%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $2.11
Upside: +279.15%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.24
Upside: +709.72%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $74.96
Upside: +61.42%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $10.71
Upside: +68.15%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $6.95
Upside: +87.05%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.06
Upside: +195.57%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.85
Upside: +145.61%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.34
Upside: +178.52%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.02
Upside: +392.61%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.75
Upside: +11,328.57%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.04
Upside: +99.00%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $7.76
Upside: +5,767.18%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $18.70
Upside: +215.51%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $179.31
Upside: +0.39%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.29
Upside: +9,506.99%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.42
Upside: +16.70%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $0.85
Upside: +2,587,827.79%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $8.85
Upside: +464.97%